Literature DB >> 25262871

Revised criteria for PCOS in WHO Group II anovulatory infertility - a revival of hypothalamic amenorrhoea?

Mette Petri Lauritsen1, Anja Pinborg, Anne Loft, Jørgen Holm Petersen, Anne Lis Mikkelsen, Marianne Rich Bjerge, Anders Nyboe Andersen.   

Abstract

OBJECTIVE: To evaluate revised criteria for polycystic ovarian morphology (PCOM) in the diagnosis of polycystic ovary syndrome (PCOS) in anovulatory infertility.
DESIGN: Prospective cohort study. PATIENTS: WHO Group II anovulatory infertile women (n = 75). MEASUREMENTS: Clinical, sonographic and endocrine parameters, including anti-Müllerian hormone (AMH).
RESULTS: The Rotterdam criteria for PCOM (antral follicle count (AFC) ≥12 and/or ovarian volume >10 ml) were fulfilled in 93% of the women. The PCOM prevalence was 68% when increasing the threshold to AFC >20 and 76% according to an AMH-based threshold of >35 pmol/l. The most recently proposed AFC ≥ 25 threshold reduced the PCOM prevalence to 52% (n = 39), leaving 48% (n = 36) without features of PCOM. Comparing the 36 women with non-PCOM with the 39 women in the PCOM group according to AFC ≥ 25, 22% vs 59% (P = 0·001) had serum LH >10 IU/l, 11% vs 41% (P = 0·003) had an LH/FSH ratio >2 and 19% vs 41% (P = 0·04) had hirsutism and/or elevated total testosterone, free testosterone, and/or androstenedione. The non-PCOM group included significantly more women with secondary infertility. The median AMH in the non-PCOM group was 47 pmol/l, which was twofold lower than in the PCOM group but above the upper limit of normo-ovulatory women.
CONCLUSIONS: According to a revised threshold of 25 follicles, almost half the anovulatory infertile women do not have PCOM. The characteristics of these women may be compatible with hypothalamic anovulation, but according to AMH levels, the ovaries remain multifollicular. PERSPECTIVES: A better distinction between hypothalamic amenorrhoea and PCOS could improve treatment strategies for anovulatory infertility.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25262871     DOI: 10.1111/cen.12621

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Anti-Müllerian hormone is all you need: an assisted reproductive technology perspective in diagnosing polycystic ovary syndrome.

Authors:  Kate McCullough; William Ledger
Journal:  Womens Health (Lond)       Date:  2016-05-11

Review 2.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

3.  Patients' auto report of regularity of their menstrual cycles. Medical history is very reliable to predict ovulation. A cross-sectional study.

Authors:  Reinaldo S A Sasaki; Mario S Approbato; Mônica C S Maia; Eliamar Aparecida de B Fleury; Christiane R Giviziez; Neuma Zanluchi
Journal:  JBRA Assist Reprod       Date:  2016-08-01

Review 4.  Current understanding of hypothalamic amenorrhoea.

Authors:  Rachel E Roberts; Linda Farahani; Lisa Webber; Channa Jayasena
Journal:  Ther Adv Endocrinol Metab       Date:  2020-07-30       Impact factor: 3.565

5.  Dysglycemia, Not Altered Sex Steroid Hormones, Affects Cognitive Function in Polycystic Ovary Syndrome.

Authors:  Brittany Y Jarrett; Natalie Vantman; Reid J Mergler; Eric D Brooks; Roger A Pierson; Donna R Chizen; Marla E Lujan
Journal:  J Endocr Soc       Date:  2019-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.